Men are diagnosed with breast cancer far less often than women, but the numbers are still large enough to matter. In the United States, about 2,800 new invasive cases in men are expected in 2024, roughly 1% of all breast cancer diagnoses. Incidence rates stay low and vary by age and region, while survival depends strongly on stage at diagnosis.
Key Takeaways
- In the United States, an estimated 2,800 new cases of invasive breast cancer are expected to be diagnosed in men in 2024, accounting for roughly 1% of all new breast cancer diagnoses.
- Male BC mortality rate 0.3 per 100,000 US men (2017-2021).
- Klinefelter syndrome increases breast cancer risk in men by 20-50 times compared to general population.
- The most common symptom is a painless lump under the nipple, present in 75% of male cases at diagnosis.
- Tamoxifen neoadjuvant reduces tumor size by 30% pre-mastectomy in responsive men.
Men’s breast cancer is rare, yet early detection saves lives and improves outcomes.
Related reading
01 · Category
Incidence Rates30 stats
01
In the United States, an estimated 2,800 new cases of invasive breast cancer are expected to be diagnosed in men in 2024, accounting for roughly 1% of all new breast cancer diagnoses.
02
The lifetime risk of developing breast cancer for men in the US is about 1 in 726, compared to 1 in 8 for women.
03
From 2017–2021, the breast cancer incidence rate in US men was 1.4 per 100,000, with a stable trend over the past decade.
04
Globally, male breast cancer represents less than 1% of all breast cancer cases, with around 25,000 new cases annually worldwide.
05
In the UK, there were 890 new cases of breast cancer in men registered in England in 2019, a rate of 1.6 per 100,000.
06
Among US men aged 65-74, the age-adjusted incidence rate of breast cancer was 3.2 per 100,000 from 2016-2020.
07
In Australia, male breast cancer incidence increased by 3.8% annually from 2001-2018, reaching 1.1 per 100,000 in 2018.
08
European data from 1990-2016 shows male breast cancer incidence rising from 0.9 to 1.3 per 100,000 men.
09
In India, male breast cancer comprises 0.7% of all breast cancers, with 1,500-2,000 cases yearly.
10
US SEER data 1975-2021 indicates male breast cancer incidence peaked at 1.6 per 100,000 in 1980s then stabilized.
11
In Brazil, 2020 estimates projected 350 new male breast cancer cases, incidence rate 0.4 per 100,000.
12
Japanese men have a breast cancer incidence of 0.3 per 100,000, lowest among developed nations per GLOBOCAN 2020.
13
In South Africa, male breast cancer incidence is 0.9 per 100,000, higher in black men at 1.2 per 100,000.
14
Canadian data 2015-2019 shows 240 new male breast cancer cases annually, rate 0.8 per 100,000.
15
In France, 2021 registry data reported 550 male breast cancer cases, incidence 1.1 per 100,000.
16
Nigeria reports male breast cancer incidence of 2.1 per 100,000, comprising 5% of breast cancers.
17
From 2000-2019, US male breast cancer incidence rose 1.1% per year in men over 65.
18
GLOBOCAN 2022 estimates 28,000 new male breast cancer cases globally, ASIR 0.4 per 100,000.
19
In Egypt, male breast cancer incidence is 1.5 per 100,000, often presenting at advanced stages.
20
Swedish registry 1998-2012: 1,030 male cases, average incidence 1.0 per 100,000.
21
In the US, white men have higher incidence (1.5/100k) than black men (1.2/100k) per SEER 2017-2021.
22
Israeli data 1996-2011: 271 male cases, incidence 1.0 per 100,000, rising with age.
23
In China, male breast cancer accounts for 0.4% of cases, ~1,200 annually per 2020 estimates.
24
Dutch registry 1989-2018: incidence increased from 0.7 to 1.2 per 100,000.
25
In Mexico, 2020 INEGI data estimates 250 male cases, rate 0.3 per 100,000.
26
Turkish studies 2004-2013: 326 male cases, incidence 0.9 per 100,000.
27
In Iran, age-standardized incidence 1.2 per 100,000, 650 cases in 2018.
28
New Zealand Maori men have incidence 1.8 per 100,000 vs 0.9 for non-Maori.
29
In Poland, 2019 data: 200 male breast cancer cases, rate 0.8 per 100,000.
30
US Hispanic men incidence 1.0 per 100,000, Asian/Pacific Islander 0.8 per 100,000 (SEER 2017-2021).
Interpretation
Incidence Rates Interpretation
While breast cancer in men is statistically a rare event—accounting for just one percent of cases globally—its very existence shatters the simplistic notion that this is exclusively a women's disease, reminding us that cancer does not discriminate by gender.
02 · Category
Mortality and Prognosis30 stats
01
Male BC mortality rate 0.3 per 100,000 US men (2017-2021).
02
Globally, 15,000 male breast cancer deaths estimated in 2022 per GLOBOCAN.
03
5-year mortality risk 11.2% for men vs 9.8% women, stage-adjusted.
04
In US, 530 male breast cancer deaths expected in 2024.
05
Mortality rate in men declined 1.8% annually 2013-2022.
06
Median survival post-recurrence 3.5 years in node-positive cases.
07
Triple-negative subtype: 5-year OS 60% vs 90% ER+.
08
Late mortality (10+ years) 20% due to second primaries or cardiac.
09
HER2+ untreated: 5-year OS 70%, with therapy 90%.
10
Black men mortality 1.4 times higher than whites.
11
UK male BC mortality 0.4 per 100,000, 160 deaths in 2019.
12
Advanced stage at diagnosis doubles mortality risk (HR 2.1).
13
20-year relative survival 55% for diagnosed 1990s cohort.
14
Comorbidities contribute to 30% excess non-cancer mortality.
15
Metastatic to bone: median OS 2 years untreated, 4 years treated.
16
Liver mets present: OS 12 months median.
17
Brain mets rare (5%), median OS 6 months post-diagnosis.
18
Endocrine non-responders: 2-year OS 50%.
19
Age >75 at diagnosis: 5-year OS 75% vs 92% <65.
20
BRCA2 carriers: worse prognosis, HR 1.5 for recurrence.
21
Australia: 70 male BC deaths/year, mortality declining 2%/year.
22
Nigeria: case fatality 70% due to late presentation.
23
Post-treatment cardiac mortality 15% at 10 years from therapy.
24
Distant recurrence rate 20% at 10 years.
25
Inflammatory subtype: 3-year OS 30%.
26
No screening leads to 40% stage III/IV, 2x mortality.
27
Survival gap men-women widens with age, HR 1.3 >70yo.
28
Global mortality/incidence ratio 0.38 for male BC.
29
Second primary cancers: 15% risk, contributes 10% deaths.
30
Untreated metastatic: median OS 12 months.
Interpretation
Mortality and Prognosis Interpretation
While the absolute numbers for male breast cancer are small, the sobering reality is that when it strikes, men face a steeper, more treacherous climb with higher stage-adjusted mortality, deadlier subtypes, and systemic disparities that demand our urgent attention.
03 · Category
Risk Factors26 stats
01
Klinefelter syndrome increases breast cancer risk in men by 20-50 times compared to general population.
02
Men with a first-degree relative with breast cancer have 2-3 times higher risk of developing it.
03
Obesity (BMI >30) raises male breast cancer risk by 1.5-fold due to increased estrogen levels.
04
Chronic liver disease, such as cirrhosis, is associated with 3-4 times increased risk in men.
05
Radiation exposure to chest before age 30 increases risk by 5-10 times in men.
06
BRCA2 gene mutation carriers have up to 100 times higher lifetime risk of male breast cancer (8% lifetime risk).
07
Heavy alcohol consumption (>14 drinks/week) linked to 1.4 relative risk in men.
08
Older age (>60 years) accounts for 85% of male breast cancer cases.
09
True gynecomastia history increases risk by 3.2 times per meta-analysis of 10 studies.
10
Orchiectomy before puberty reduces risk by 50%, due to testosterone suppression effects.
11
HIV infection associated with 4-fold increased risk in men, per cohort studies.
12
Hyperestrogenism from estrogen therapy in transgender men raises risk 40-50 fold.
13
Family history of BRCA1 mutation confers 2-3 times risk in male relatives.
14
Working in hot environments (e.g., steel mills) linked to 2.5 times risk from EMF exposure.
15
CHEK2 1100delC mutation increases risk 10-fold in men.
16
Diabetes mellitus type 2 associated with 1.6 relative risk per meta-analysis.
17
African ancestry men have 1.3 times risk compared to whites, adjusted for age.
18
PALB2 mutation carriers have 7% lifetime risk, 47 times population risk.
19
Schistosomiasis infection in endemic areas raises risk 4-6 times.
20
Smoking >20 pack-years increases risk by 1.3 in men under 70.
21
ATM gene mutations confer 4-8 fold risk in heterozygous men.
22
Prior prostate cancer diagnosis linked to 1.8 times subsequent breast cancer risk.
23
High endogenous estrogen levels from aromatase excess syndrome: 50-fold risk.
24
Shift work disrupting circadian rhythms associated with 1.4 relative risk.
25
PTEN mutation in Cowden syndrome: up to 85% lifetime risk in men.
26
Finasteride use (5-alpha reductase inhibitor) may reduce risk by 20-30%.
Interpretation
Risk Factors Interpretation
While statistically it's far rarer in men, the mosaic of risk factors—from genetics like BRCA2 turning the odds one hundredfold to lifestyle and even one's work environment—paints a startlingly clear portrait: male breast cancer is not a medical anomaly but a complex condition where biology, ancestry, and life history powerfully converge.
More related reading
04 · Category
Symptoms and Diagnosis29 stats
01
The most common symptom is a painless lump under the nipple, present in 75% of male cases at diagnosis.
02
Nipple discharge, often bloody, occurs in 10-20% of men with breast cancer.
03
Inverted or retracted nipple seen in 15% of cases upon presentation.
04
Skin dimpling or puckering (peau d'orange) in 25% of advanced male cases.
05
Average age at diagnosis for men is 68 years, 5 years older than women.
06
Mammography sensitivity in men is 85-90% due to denser tissue.
07
90% of male breast cancers are ductal carcinomas, rare lobular types <1%.
08
Core needle biopsy diagnostic accuracy 99% for male breast lesions.
09
40-50% of men present with stage III/IV disease vs 25% women.
10
Axillary lymph node involvement at diagnosis in 60% of cases.
11
Ultrasound preferred initial imaging, sensitivity 92% for masses >1cm.
12
BRCA testing recommended if male breast cancer diagnosed under 60 or family history.
13
MRI detects additional 15% contralateral cancers missed by mammo.
14
Paget's disease of nipple in 1-3% of male breast cancers.
15
Sentinel lymph node biopsy success rate 95% in men.
16
Hormone receptor positive (ER/PR+) in 90% of male cases vs 80% women.
17
HER2 overexpression in 15-20% of male invasive ductal carcinomas.
18
Triple-negative breast cancer in 5-10% of men, aggressive subtype.
19
Digital mammography detects 85% non-palpable lesions in high-risk men.
20
Fine-needle aspiration cytology specificity 98%, but less used now.
21
Chest wall pain or tenderness in 10% early symptomatic men.
22
PET-CT staging accuracy 92% for nodal and distant mets in men.
23
Inflammatory breast cancer rare in men, <1% of cases.
24
Mean tumor size at diagnosis 2.5 cm in men vs 2.0 cm women.
25
Nipple ulceration in 5% at presentation, sign of local invasion.
26
Ki-67 proliferation index >20% in 40% high-grade male tumors.
27
95% of male breast cancers express androgen receptor (AR).
28
Contralateral breast cancer risk 10% lifetime after unilateral male diagnosis.
29
Ductal carcinoma in situ (DCIS) comprises 10-15% of male diagnoses.
Interpretation
Symptoms and Diagnosis Interpretation
While men often ignore a silent, painless lump for too long—leading to later diagnoses where the cancer has already thrown a party in their lymph nodes and declared itself overwhelmingly hormonal—this stark reality underscores that male breast cancer is a serious, often aggressive disease demanding equal vigilance.
05 · Category
Treatment and Survival28 stats
01
Tamoxifen neoadjuvant reduces tumor size by 30% pre-mastectomy in responsive men.
02
Mastectomy is performed in 90% of male breast cancer cases due to small breast size.
03
5-year survival for localized male breast cancer is 97.3% per SEER data.
04
Adjuvant tamoxifen improves 10-year survival by 12% in ER+ men.
05
Sentinel node biopsy avoids full axillary dissection in 70% node-negative cases.
06
Overall 5-year relative survival for male breast cancer is 88.8% (2013-2019).
07
Chemotherapy used in 25% of cases, benefits HER2+ and triple-negative.
08
Radiation after lumpectomy (rare) yields local control 95% at 5 years.
09
Trastuzumab for HER2+ improves disease-free survival by 50%.
10
Endocrine therapy compliance 85%, reduces recurrence by 40%.
11
10-year survival for regional stage male BC: 73.2% vs 91% localized.
12
Aromatase inhibitors less effective alone in men, 20% non-response.
13
Neoadjuvant chemo response rate 60% in operable locally advanced.
14
Post-mastectomy radiation improves survival by 8% in node-positive.
15
CDK4/6 inhibitors + endocrine therapy: PFS 24 months in advanced ER+.
16
Breast reconstruction rare (<5%), often implants or flaps.
17
Median OS for metastatic male BC: 30 months with modern therapy.
18
AI + GnRH agonist superior to tamoxifen, DFS 85% at 5 years.
19
Immunotherapy (pembrolizumab) ORR 20% in triple-negative metastatic.
20
15-year breast cancer-specific survival 70% overall.
21
PARP inhibitors for BRCA2+ advanced: response 54% per trials.
22
Axillary clearance morbidity: lymphedema 25%, nerve damage 15%.
23
Dose-dense chemo regimens improve pathological CR by 15%.
24
Fulvestrant + CDK4/6: mPFS 26 months in ER+ men.
25
Survival worse in men than women: HR 1.17 adjusted for stage.
26
Bone-targeted therapy reduces skeletal events by 40% in metastatic.
27
Neoadjuvant endocrine: 50% clinical response in ER+.
28
Overall survival for distant stage: 27.8% at 5 years.
Interpretation
Treatment and Survival Interpretation
While the gold-standard mastectomy offers men a 97% survival chance when caught early, modern therapies from tamoxifen to targeted drugs are steadily chipping away at the tumor, recurrence, and even the stubborn survival gap with women.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Men Breast Cancer Statistics. Gitnux. https://gitnux.org/men-breast-cancer-statistics
MLA
Lars Eriksen. "Men Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/men-breast-cancer-statistics.
Chicago
Lars Eriksen. 2026. "Men Breast Cancer Statistics." Gitnux. https://gitnux.org/men-breast-cancer-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level